Tarsus Pharmaceuticals Inc logo

TARS

Tarsus Pharmaceuticals Inc

$16.22

Earnings Summary

Revenue
$0.54Mn
Net Profits
$-20.24Mn
Net Profit Margins
-3754.73%

Highlights

Revenue:

Tarsus Pharmaceuticals Inc’s revenue fell -98.39% since last year same period to $0.54Mn in the Q1 2022. On a quarterly growth basis, Tarsus Pharmaceuticals Inc has generated 59.47% jump in its revenue since last 3-months.

Net Profits:

Tarsus Pharmaceuticals Inc’s net profit fell -295.05% since last year same period to $-20.24Mn in the Q1 2022. On a quarterly growth basis, Tarsus Pharmaceuticals Inc has generated -36.27% fall in its net profits since last 3-months.

Net Profit Margins:

Tarsus Pharmaceuticals Inc’s net profit margin fell -12197.93% since last year same period to -3754.73% in the Q1 2022. On a quarterly growth basis, Tarsus Pharmaceuticals Inc has generated 14.54% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Tarsus Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.65
EPS Estimate Current Year
-0.65

Highlights

EPS Estimate Current Quarter:

Tarsus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.65 - a 29.35% jump from last quarter’s estimates.

EPS Estimate Current Year:

Tarsus Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.65.

Key Ratios

Key ratios of the Tarsus Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.98
Return on Assets (ROA)
-0.04
Return on Equity (ROE)
-0.08
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Tarsus Pharmaceuticals Inc’s earning per share (EPS) fell -308.51% since last year same period to -0.98 in the Q1 2022. This indicates that the Tarsus Pharmaceuticals Inc has generated -308.51% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Tarsus Pharmaceuticals Inc’s return on assets (ROA) stands at -0.04.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Tarsus Pharmaceuticals Inc’s return on equity (ROE) stands at -0.08.

Dividend Per Share (DPS):

Tarsus Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.92
-0.98
-6.52%

Company Information

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.

Organisation
Tarsus Pharmaceuticals Inc
Employees
20
Industry
Health Technology